Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

André, Thierry; Lonardi, Sara; Wong, Ka Yeung Mark; Lenz, H.J.; Gelsomino, Fabio; Aglietta, Massimo; Morse, Michael A.; Cutsem, Eric Van; McDermott, Ray; Hill, Andrew; Sawyer, Michael B.; Hendlisz, Alain; Neyns, Bart; Abdullaev, Sandzhar; Memaj, Arteid; Lei, Ming; Dixon, Michael F.; Kopetz, Scott; Overman, Michael J.

doi:10.1016/j.annonc.2022.06.008

articleAnnals of OncologyJun 25, 2022HYBRID OA

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

TAThierry André SLSara Lonardi KYKa Yeung Mark Wong HLH.J. Lenz FGFabio Gelsomino

Hôpital Saint-Antoine · Centre de Recherche Saint-Antoine · +19 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

•In previously treated MSI-H/dMMR mCRC, nivolumab plus ipilimumab showed durable benefit with 4 years of follow-up.•ORR was 65%. The 48-month rates of progression-free survival and overall survival were 53% and 71%, respectively.•Significant and clinically meaningful improvements in quality of life were largely maintained with continuous treatment.•No new safety signals were identified, with a low rate (13% of patients) of any-grade TRAEs leading to discontinuation.•These results show the long-term benefit of nivolumab plus low-dose ipilimumab in previously treated MSI-H/dMMR mCRC. BackgroundIn the phase II multicohort CheckMate 142 study, nivolumab plus low-dose (1 mg/kg) ipilimumab provided robust and…

Citation impact

250

total citations

FWCI: 23.50
Percentile: 100%
References: 21

Citations per year

Authors

19

Topics & keywords

Topics

Keywords

Ipilimumab
Nivolumab
Medicine
Microsatellite instability
Colorectal cancer
Internal medicine
Oncology
Cancer

No related works found for this paper.